selected scholarly activity
-
conferences
- ASSESSMENT OF THE COST-EFFECTIVENESS OF RISK FACTOR GUIDED PROPHYLAXIS WITH PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN COLOMBIAN INFANTS BORN AT 32-35 WEEKS' GESTATIONAL AGE. Value in Health. S156-S156. 2023
- OPTIMIZING THE USE OF RISK FACTORS TO GUIDE THE COST-EFFECTIVE USE OF PALIVIZUMAB PROPHYLAXIS AGAINST SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN INFANTS BORN 32-35 WEEKS' GESTATIONAL AGE. Value in Health. S125-S125. 2023
- A 10-year population-based prevalence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB106-AB106. 2023
- A 10-year population-based prevalence study of the burden of palmoplantar pustulosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB107-AB107. 2023
- A 3-year population-based incidence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB107-AB107. 2023
- A 3-year population-based incidence study of the burden of palmoplantar pustolosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB107-AB107. 2023
- ONE- AND FIVE-YEAR SURVIVAL AFTER FRAGILITY FRACTURE: REAL-WORLD RETROSPECTIVE MATCHED-COHORT STUDY IN ONTARIO, CANADA. Aging - Clinical and Experimental Research. S145-S145. 2023
- One- and five-year survival after fragility fracture: Real-world retrospective matched-cohort study in Ontario, Canada. Journal of Bone and Mineral Research. 80-81. 2023
- DEVELOPMENT AND APPLICATION OF A NEW COST-UTILITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN MODERATE-TO-LATE PRETERM INFANTS. Value in Health. S137-S138. 2022
- TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG GENERALIZED PUSTULAR PSORIASIS PATIENTS: A CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS. Value in Health. S228-S228. 2022
- TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG PALMOPLANTAR PUSTOLOSIS PATIENTS: A 10-YEAR CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS. Value in Health. S220-S220. 2022
- Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. S196-S196. 2022
- BARIATRIC SURGERY AS SECONDARY PREVENTION FOR CARDIOVASCULAR DISEASE: A POPULATION-BASED MATCHED COHORT STUDY IN A UNIVERSAL HEALTHCARE SYSTEM Cardiovascular risk and bariatric surgery. Obesity Surgery. 76-77. 2022
- THE SUSTAINED RISK OF OBESITY ON BREAST CANCER INCIDENCE AFTER SURGICAL WEIGHT LOSS: A POPULATION-BASED, MULTIPLE-MATCHED COHORT STUDY. Obesity Surgery. 558-558. 2022
- COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS. Value in Health. S428-S428. 2022
- Burden of Paget's Disease of Bone: Temporal Trend Over 20 years in Quebec, Canada. Journal of Bone and Mineral Research. 77-77. 2022
- Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study. Blood. 4990-4990. 2021
- The Fragility Hip Fracture: Not only a Marked Burden of Disease, but also a Significant Predictor of Subsequent Hip Fracture Risk. Journal of Bone and Mineral Research. 225-226. 2020
- Real-world cost-effectiveness of direct oral anticoagulants in the Quebec setting. Pharmacoepidemiology and Drug Safety. 314-314. 2020
- REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA. Journal of Bone and Mineral Research. 105-105. 2019
- REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA. Journal of Bone and Mineral Research. 105-105. 2019
- Real-World Outcomes and Imminent Fractures After Index Fragility Fracture: A Population Study. Journal of Bone and Mineral Research. 105-105. 2019
- Real-World Outcomes and Imminent Fractures After Index Fragility Fracture: A Population Study. Journal of Bone and Mineral Research. 105-105. 2019
- ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS. Value in Health. S521-S521. 2019
- A simulation-based comparison of confounding adjustment methods in observational studies of administrative data. Pharmacoepidemiology and Drug Safety. 71-72. 2019
- The devil you should know: Adjustment for confounding bias is rare in observational economic evaluations in cardiology. Pharmacoepidemiology and Drug Safety. 303-304. 2019
- Outcomes from a Multicentre Pilot Randomized Clinical Trial of Early In-Bed Cycling with Mechanically Ventilated Patients: CYCLE Pilot RCT. American Journal of Respiratory and Critical Care Medicine. 2018
- MP11-14 COST EFFECTIVENESS OF TARGETED ANTIMICROBIAL THERAPY IN TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY. Investigative Urology. E142-E142. 2017
- Cycle Pilot Rct: A Multicenter Feasibility Study Of Early In-Bed Cycling Versus Routine Physiotherapy In Medical- Surgical Ventilated Patients. American Journal of Respiratory and Critical Care Medicine. 2017
- Indirect Costs Associated with Cardiovascular Disease in Canada: A Literature Review. Value in Health. A49-A49. 2016
- Propensity Score Matching Does not Always Remove Confounding within an Economic Evaluation Based on a Non-Randomized Study. Value in Health. A338-A338. 2015
- Psychiatric Healthcare Utilization and Related Costs in Newly Diagnosed Individuals with Autism Spectrum Disorder (ASD) in Quebec (Canada). Pharmacoepidemiology and Drug Safety. 278-279. 2015
- Concomitant Use of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) And Proton Pump Inhibitors (Ppis) in Newly Diagnosed Patients With Osteoarthritis (Oa), Rheumatoid Arthritis (Ra) or Ankylosing Spondylitis (As). Value in Health. A390-A390. 2014
- Follow-Up of Psychoactive Drug Use in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada). Pharmacoepidemiology and Drug Safety. 95-96. 2014
- Psychiatric Health Care Utilisation and Related Costs in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada). Pharmacoepidemiology and Drug Safety. 280-280. 2014
- A systematic review of methodological frameworks for evaluation of ethical considerations in health technology assessment. Value in Health. A200-A200. 2014
- Follow-Up Of Psychoactive Drug Use In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada). Value in Health. A155-A156. 2014
- Psychiatric Health Care Utilisation And Related Costs In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada). Value in Health. A158-A158. 2014
- Assessment of a Canadian Primary Care Electronic Medical Record Database for Use in Observational Studies. Value in Health. A582-A582. 2013
- Psychoactive Drug Use, Polypharmacy and Co-Morbidities in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec. Value in Health. A552-A552. 2013
- Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism (JCEM). E1072-E1087. 2013
- How can we use discrete event simulation to improve access to health care: an assessment of increasing access to care for children with medically refractory epilepsy. Value in Health. A108-A109. 2013
- CHARACTERISTICS OF THE ABORIGINAL PEOPLE WITH DIABETES IN THE SOUTH-WESTERN OF ONTARIO, CANADA. Value in Health. A495-A496. 2012
- PDB34 Economic Evaluation of Treating Diabetes Patients According to Guidelines in South-Western Ontario, Canada. Value in Health. A499-A499. 2012
- PDB77 Characteristics of Patients With Diabetes in Southwestern Ontario, Canada. Value in Health. A507-A507. 2012
- PHP202 Bridging the Gap Between Institutional Levels Using Systems Analysis. Value in Health. A325-A325. 2012
- Relative, Reliability-Adjusted Diagnostic Test Accuracy of Erosion Detection Between Magnetic Resonance Imaging and Radiography in Rheumatoid Arthritis. Arthritis and Rheumatism. S888-S888. 2012
- The Effect of Evaluation Variability At the Unit of Measurement On the Reliability of Omeract Ramris and Van Der Heijde-Modified Sharp Score.. Arthritis and Rheumatism. S440-S440. 2012
- PMD8 Efficacy of Systemic Hyperbaric Oxygen Therapy for Non-Healing Diabetic Ulcers of the Lower Limb: Systematic Review and Meta-Analysis. Value in Health. A63-A63. 2012
- PRM28 Physicians as Pseudo-Agents in a Hospital Emergency Department Discrete Event Simulation. Value in Health. A163-A163. 2012
- 2015 CHANGES IN ERECTILE FUNCTION AFTER PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA. Investigative Urology. E813-E814. 2012
- PCN175 Reimbursement of Anticancer Drugs in Canada: What Can We Learn from the Nice New Appraisal Process for Life-Extending End-of-Life Treatments?. Value in Health. A466-A466. 2011
- PCV50 Hospital Costs Associated with Atrial Fibrillation in Canada. Value in Health. A373-A373. 2011
- PMD86 A Systematic Review of Economic Evaluations Conducted for Assessment of Genetic Testing Technologies. Value in Health. A260-A260. 2011
- PMH26 Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte-Carlo Markov Model. Value in Health. A291-A291. 2011
- PMS22 The Burden of Illness of Osteoporosis in Canada. Value in Health. A306-A306. 2011
- Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte-Carlo Markov Model. Pharmacoepidemiology and Drug Safety. S195-S195. 2011
- PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS: A CANADIAN COST EFFECTIVENESS ANALYSIS. Value in Health. A119-A120. 2011
- PSY48 A WORKPLACE HEALTH PROGRAM FOR BRITISH COLUMBIA PUBLIC SERVICE AGENCY (CANADA). Value in Health. A68-A68. 2011
- PUK6 LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Value in Health. A75-A75. 2011
- PMS21 THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES IN CANADA. Value in Health. A306-A306. 2010
- Factors Associated with the Schizophrenia Specific States: A Population-Based Study. Pharmacoepidemiology and Drug Safety. S274-S275. 2010
- Validation of a Monte-Carlo Markov Model for Schizophrenia. Pharmacoepidemiology and Drug Safety. S153-S154. 2010
- HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO. Value in Health. A133-A133. 2010
- PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY. Value in Health. A211-A211. 2010
- UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO. Value in Health. A133-A134. 2010
- DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES. Value in Health. A234-A234. 2009
- MC6 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION. Value in Health. A488-A489. 2009
- MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R. Value in Health. A226-A227. 2009
- PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS. Value in Health. A405-A405. 2009
- PMC35 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION. Value in Health. A393-A393. 2009
- PMH18 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE. Value in Health. A353-A353. 2009
- PMH2 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE. Value in Health. A520-A520. 2009
- PND31 HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMER'S DISEASE HEALTH STATE: A CANADIAN SURVEY OF THE GENERAL PUBLIC. Value in Health. A371-A371. 2009
- PND47 ASSESSING CANADIANS' WILLINGNESS-TO-PAY FOR ALZHEIMER'S DISEASE MEDICATIONS. Value in Health. A374-A374. 2009
- PND48 SUPPORT FOR PROVIDING UNRESTRICTED ACCESS TO AN ALZHEIMER'S DISEASE MEDICATION IN CANADA: RESULTS FROM A STUDY OF THE GENERAL POPULATION. Value in Health. A374-A375. 2009
- PSY18 THE BURDEN OF OBESITY IN ONTARIO. Value in Health. A378-A378. 2009
- PGI6 COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR REFRACTORY ULCERATIVE COLITIS. Value in Health. A58-A58. 2009
- PND26 UTILITIES FOR MODERATE ALZHEIMER'S DISEASE: RESULTS FROM A SURVEY OF THE GENERAL PUBLIC IN CANADA. Value in Health. A194-A194. 2009
- PSY9 USING UTILIZATION RECORDS TO ESTIMATE THE BURDEN OF OBESITY IN ADULTS LIVING IN ONTARIO. Value in Health. A131-A131. 2009
- QL3 ESTIMATION OF UTILITY VALUES FOR DIABETESXD-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA. Value in Health. A17-A17. 2009
- PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?. Value in Health. A51-A51. 2008
- PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS. Value in Health. A173-A174. 2008
- PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT. Value in Health. A265-A265. 2008
- Clinical and autonomic predictors for head-up tilt table test response in patients with suspected vasovagal syncope. Canadian Journal of Cardiology. 63C-63C. 2007
- PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS. Value in Health. A361-A361. 2006
- CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA. Value in Health. A8-A8. 2006
- PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES: RESULTS FROM A COMPUTERIZED SIMULATION MODEL. Value in Health. A33-A34. 2006
- PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS: RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY. Value in Health. A36-A36. 2006
- PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?. Value in Health. A56-A56. 2006
- PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA). Value in Health. A173-A173. 2006
- Current prevalence and control of dyslipidemia in the primary care setting. Circulation. E355-E355. 2005
- Prescription choices for treatment and control of dyslipidemia in primary care. Circulation. E355-E355. 2005
-
journal articles
- Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses. PharmacoEconomics - Open. 8:823-836. 2024
- Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses.. PharmacoEconomics - Open. 8:963-965. 2024
- Systematic methodological review of health state values in glaucoma cost-utility analyses. European Journal of Health Economics. 25:1417-1435. 2024
- Economic evaluation of the “paramedics and palliative care: bringing vital services to Canadians” program compared to the status quo. Canadian Journal of Emergency Medicine. 26:671-680. 2024
- A scoping review of costing methodologies used to assess interventions for underserved pregnant people and new parents.. International Journal for Equity in Health. 23:168. 2024
- Cost Evaluation of the Ontario Virtual Urgent Care Pilot Program: Population-Based, Matched Cohort Study. Journal of Medical Internet Research. 26:e50483-e50483. 2024
- Cost-effectiveness analysis of health tapestry, a complex primary care program for older adults: a post-hoc analysis. BMC Primary Care. 25:235. 2024
- Early In-Bed Cycle Ergometry in Mechanically Ventilated Patients. NEJM Evid. 3:EVIDoa2400137. 2024
- ROBVALU: a tool for assessing risk of bias in studies about people’s values, utilities, or importance of health outcomes. The BMJ. 385:e079890-e079890. 2024
- Scoping review of the recommendations and guidance for improving the quality of rare disease registries. Orphanet Journal of Rare Diseases. 19:187. 2024
- Coordination of oral anticoagulant care at hospital discharge (COACHeD): pilot randomised controlled trial. BMJ Open. 14:e079353-e079353. 2024
- Improving medication prescribing-related outcomes for vulnerable elderly in transitions on high-risk medications (IMPROVE-IT HRM): a pilot randomized trial protocol. Pilot and Feasibility Studies. 10:60. 2024
- Economic evaluation of non-invasive liver tests for the diagnosis of liver fibrosis in chronic liver diseases: a systematic review protocol. JBI evidence synthesis. 22:681-688. 2024
- Postfracture survival in a population-based study of adults aged ≥66 yr: a call to action at hospital discharge. JBMR Plus. 8:ziae002. 2024
- Robot-assisted partial knee replacement versus standard total knee replacement (RoboKnees): a protocol for a pilot randomized controlled trial. Pilot and Feasibility Studies. 10:39. 2024
- Opioid reduction and enhanced recovery in orthopaedic surgery (OREOS): a protocol for a feasibility randomised controlled trial in patients undergoing total knee arthroplasty. Pilot and Feasibility Studies. 10:30. 2024
- Association between children’s caregivers time preferences and childhood overweight and obesity in Mexico. PLoS ONE. 19:e0283455-e0283455. 2024
- Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials. BMJ Open. 14:e068182-e068182. 2024
- The relationship between patient experience and real-world digital health access in primary care: A population-based cross-sectional study. PLoS ONE. 19:e0299005-e0299005. 2024
- Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of Medical Economics. 26:630-643. 2023
- EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age. Value in Health. 26:S125-S125. 2023
- EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age. Value in Health. 26:S156-S156. 2023
- Health care utilization and outcomes of patients seen by virtual urgent care versus in-person emergency department care. CANADIAN MEDICAL ASSOCIATION JOURNAL. 195:E1463-E1474. 2023
- Prevalence and incidence of Paget's disease of bone: Temporal trend over 20 years in the province of Quebec, Canada. Bone. 176:116895-116895. 2023
- Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis. 7:102228-102228. 2023
- 50 New Analysis on the Cost-effectiveness of Palivizumab (PVZ) for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Canadian Infants Born 29-31 and 32-35 weeks’ Gestational Age (wGA). Paediatrics and Child Health. 28:e22-e22. 2023
- Motivational interviewing to promote healthy behaviors for obesity prevention in young adults (MOTIVATE): a pilot randomized controlled trial protocol. Pilot and Feasibility Studies. 9:156. 2023
- 43266 A 10-year population-based prevalence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB106-AB106. 2023
- 43322 A 10-year population-based prevalence study of the burden of palmoplantar pustulosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB107-AB107. 2023
- 44100 A 3-year population-based incidence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB107-AB107. 2023
- 44118 A 3-year population-based incidence study of the burden of palmoplantar pustolosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB107-AB107. 2023
- The burden associated with generalized pustular psoriasis: A Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics. JAAD Int. 12:90-98. 2023
- The burden of palmoplantar pustulosis: A Canadian population-based study of inpatient care, emergency departments, and outpatient clinics. JAAD Int. 12:151-159. 2023
- A longitudinal study evaluating adverse childhood experiences and obesity in adulthood using the Canadian Longitudinal Study on Aging (CLSA). International Journal of Epidemiology. 52:1100-1111. 2023
- Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for Glaucoma. Value in Health. 26:1249-1257. 2023
- Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data. Current Oncology. 30:6596-6608. 2023
- Critical Care Cycling to ImproveLowerExtremity Strength (CYCLE): protocol for an international, multicentre randomised clinical trial of early in-bed cycling for mechanically ventilated patients. BMJ Open. 13:e075685-e075685. 2023
- Molecular test of Paget's disease of bone in families not linked to SQSTM1 gene mutations. Bone Reports. 18:101670-101670. 2023
- Residual Risk of Breast Cancer After Bariatric Surgery. JAMA Surgery. 158:634-634. 2023
- Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants. Journal of Infectious Diseases. 227:1333-1334. 2023
- Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective. Current Oncology. 30:4688-4699. 2023
- Health TAPESTRY Ontario: A Multi-Site Randomized Controlled Trial Testing Implementation and Reproducibility. Annals of Family Medicine. 21:132-142. 2023
- Obesity and adverse childhood experiences in relation to stress during the COVID-19 pandemic: an analysis of the Canadian Longitudinal Study on Aging. International Journal of Obesity. 47:197-206. 2023
- Return on investment of Canadian tobacco control policies implemented between 2001 and 2016. Tobacco Control. 32:233-238. 2023
- Health Utilities Index Mark 3 scores for children and youth: Population norms for Canada based on cycles 5 (2016 and 2017) and 6 (2018 and 2019) of the Canadian Health Measures Survey.. Health Reports. 34:29-39. 2023
- Opioid Reduction and Enhanced Recovery in Orthopaedic Surgery (OREOS): A Protocol for a Feasibility Randomized Controlled Trial in Knee Replacement Patients 2023
- A multi-center, randomized, 12-month, parallel-group, feasibility study to assess the acceptability and preliminary impact of family navigation plus usual care versus usual care on attrition in managing pediatric obesity: a study protocol. Pilot and Feasibility Studies. 9:14. 2023
- A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age. PLoS ONE. 18:e0289828-e0289828. 2023
- Demographic characteristics, outcomes and experience of patients using virtual urgent care services from 14 emergency department led sites in Ontario. Canadian Journal of Emergency Medicine. 25:65-73. 2023
- What are effective strategies to respond to the psychological impacts of working on the frontlines of a public health emergency?. Frontiers in Public Health. 11:1282296. 2023
- “It saved me from the emergency department”: A qualitative study of patient experience of virtual urgent care in Ontario. PLoS ONE. 18:e0285468-e0285468. 2023
- Opioid reduction and enhanced recovery in orthopaedic surgery (OREOS): A feasibility randomized controlled trial in knee replacement patients. Canadian Journal of Pain. 6:1-2. 2022
- A scoping review of strategies to support public health recovery in the transition to a “new normal” in the age of COVID-19. BMC Public Health. 22:1244. 2022
- Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trial. Pilot and Feasibility Studies. 8:166. 2022
- EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants. Value in Health. 25:S137-S138. 2022
- EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S220-S220. 2022
- EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S228-S228. 2022
- EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S196-S196. 2022
- EPH46 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S200-S200. 2022
- Defining the Assisted Living Sector in Canada: An Environmental Scan. Journal of the American Medical Directors Association. 23:1871-1877.e1. 2022
- Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia. Current Oncology. 29:7624-7636. 2022
- Economic Evaluation of Early Psychosis Interventions From A Canadian Perspective. Canadian Journal of Psychiatry. 67:768-777. 2022
- Reverse Total Shoulder Arthroplasty Is the Most Cost-effective Treatment Strategy for Proximal Humerus Fractures in Older Adults: A Cost-utility Analysis. Clinical Orthopaedics and Related Research. 480:2013-2026. 2022
- The treatment of epilepsy in younger and older adults: Demographic differences and prescribing patterns of anti-seizure medications in Canada. Journal of Epilepsy. 184:106941-106941. 2022
- EE476 Cost-Effectiveness of Emicizumab Prophylaxis in Patients with Hemophilia a without Inhibitors. Value in Health. 25:S428-S428. 2022
- A review of implementation and evaluation of Pan American Health Organization's policies to prevent childhood obesity in Latin America. Obesity Science and Practice. 8:352-362. 2022
- Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Translational Psychiatry. 12:214. 2022
- Rates of health services use among residents of retirement homes in Ontario: a population-based cohort study. CANADIAN MEDICAL ASSOCIATION JOURNAL. 194:E730-E738. 2022
- A comparison of confounder selection and adjustment methods for estimating causal effects using large healthcare databases. Pharmacoepidemiology and Drug Safety. 31:424-433. 2022
- Bariatric Surgery and Breast Cancer Incidence: a Population-Based, Matched Cohort Study. Obesity Surgery. 32:1261-1269. 2022
- Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Translational Psychiatry. 12:101. 2022
- Virologic failure in people living with HIV in 1st line ART: A 10-year Mexican population-based study. International Journal of STD and AIDS. 33:363-373. 2022
- Continuous Noninvasive Remote Automated Blood Pressure Monitoring With Novel Wearable Technology: A Preliminary Validation Study. JMIR mHealth and uHealth. 10:e24916-e24916. 2022
- Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling. International Journal of Technology Assessment in Health Care. 38:e57. 2022
- Economic Evaluation of Palliative Care Interventions: A Review of the Evolution of Methods From 2011 to 2019. American Journal of Hospice and Palliative Medicine. 39:108-122. 2022
- Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. Osteoporosis International. 33:113-122. 2022
- Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID). PLoS ONE. 17:e0266663-e0266663. 2022
- Do assisted living facilities that offer a dementia care program differ from those that do not? A population-level cross-sectional study in Ontario, Canada. BMC Geriatrics. 21:463. 2021
- Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. BMC Musculoskeletal Disorders. 22:105. 2021
- Patient characteristics and determinants of CD4 at diagnosis of HIV in Mexico from 2008 to 2017: a 10-year population-based study. AIDS Research and Therapy. 18:84. 2021
- Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 22:746. 2021
- Association Between Dementia Care Programs in Assisted Living Facilities and Transitions to Nursing Homes in Ontario, Canada: A Population-Based Cohort Study. Journal of the American Medical Directors Association. 22:2115-2120.e6. 2021
- The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. Current Oncology. 28:3649-3658. 2021
- Comparison of 4-Year Health Care Expenditures Associated With Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. JAMA network open. 4:e2122079-e2122079. 2021
- Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review. BMJ Open. 11:e047511-e047511. 2021
- Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada. Osteoporosis International. 32:1753-1761. 2021
- Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology. PharmacoEconomics - Open. 5:397-410. 2021
- Unrecognized assets created by public-sector investments in health and social services. Journal of Public Budgeting, Accounting and Financial Management. 33:409-426. 2021
- Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:. Circulation. 143:1468-1480. 2021
- Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. JAMA network open. 4:e216820-e216820. 2021
- The Need for an Improved Evidence Base to Inform the Health Care Decision-making Process—Reply. JAMA Surgery. 156:399-399. 2021
- Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. BMC Musculoskeletal Disorders. 22:224. 2021
- Do Assisted Living Facilities That Offer a Dementia Care Program Differ from Those That Do Not? A Population-Level Cross-Sectional Study in Ontario, Canada 2021
- GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making. Journal of Clinical Epidemiology. 129:138-150. 2021
- Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. Journal of Medical Economics. 24:1318-1326. 2021
- Medication use and its impact on high-cost health care users among older adults: protocol for the population-based matched cohort HiCOSTT study. CMAJ open. 9:E44-E52. 2021
- One-Year Costs Associated with Hospitalizations Due to Aortic Stenosis in Canada. CJC OPEN. 3:82-90. 2021
- The impact of routine HIV drug resistance testing in Ontario: A controlled interrupted time series study. PLoS ONE. 16:e0246766-e0246766. 2021
- Health TAPESTRY Ontario: protocol for a randomized controlled trial to test reproducibility and implementation. Trials. 21:714. 2020
- Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators. BMC Cancer. 20:795. 2020
- Association Between Bariatric Surgery and All-Cause Mortality: A Population-Based Matched Cohort Study in a Universal Health Care System. ACP journal club. 173:694-703. 2020
- Is Total Hip Arthroplasty a Cost-Effective Option for Management of Displaced Femoral Neck Fractures? A Trial-Based Analysis of the HEALTH Study. Journal of Orthopaedic Trauma. 34:S37-S41. 2020
- Association of Roux-en-Y Gastric Bypass With Postoperative Health Care Use and Expenditures in Canada. JAMA Surgery. 155:e201985-e201985. 2020
- Economic evaluation of robot-assisted radical prostatectomy compared to open radical prostatectomy for prostate cancer treatment in Ontario, Canada. Journal of the Canadian Urological Association. 14:E350-E357. 2020
- Health programmes and services addressing the prevention and management of infectious diseases in persons who inject drugs in Canada: a systematic integrative review protocol. BMJ Open. 10:e035188-e035188. 2020
- A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017. Medical decision making. 40:582-595. 2020
- Health TAPESTRY Ontario: Protocol for a Randomized Controlled Trial to Test Reproducibility and Implementation 2020
- Methodological approaches to the design and analysis of nonrandomized intervention studies for the prevention of child and adolescent obesity. Canadian Journal of Public Health. 111:358-370. 2020
- Health TAPESTRY Ontario: Protocol for a Randomized Controlled Trial to Test Reproducibility and Implementation 2020
- The hidden cost of an extensive preoperative work-up: predictors of attrition after referral for bariatric surgery in a universal healthcare system. Surgical Endoscopy. 34:988-995. 2020
- Stakeholders’ feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines. Journal of Population Therapeutics and Clinical Pharmacology. 27:e1-e24. 2020
- Health TAPESTRY Ontario: Protocol for a Randomized Controlled Trial to Test Replicability and Implementation 2019
- A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers. PharmacoEconomics - Open. 3:437-451. 2019
- PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS. Value in Health. 22:S521-S521. 2019
- Use, costs, and predictors of psychiatric healthcare services following an autism spectrum diagnosis: Population-based cohort study. Autism. 23:2020-2030. 2019
- Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. BMJ Open. 9:e028637-e028637. 2019
- Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. CMAJ open. 7:E537-E545. 2019
- PMS52 REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA. Value in Health. 22:S248-S248. 2019
- Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: A systematic review and network meta-analysis. Clinical and Investigative Medicine. 42:E53-E65. 2019
- Impact of Psychoactive Drug Use on Developing Obesity among Children and Adolescents with Autism Spectrum Diagnosis: A Nested Case–Control Study. Childhood Obesity. 15:131-141. 2019
- Multicentre pilot randomised clinical trial of early in-bed cycle ergometry with ventilated patients. BMJ Open Respiratory Research. 6:e000383-e000383. 2019
- <p>A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients</p>. ClinicoEconomics and Outcomes Research. Volume 11:477-486. 2019
- <p>Electronic referral systems in health care: a scoping review</p>. ClinicoEconomics and Outcomes Research. Volume 11:325-333. 2019
- Descriptive analysis of pharmacy services provided after community pharmacy screening. International Journal of Clinical Pharmacy. 40:1577-1586. 2018
- Direct Health-Care Costs and Productivity Costs Associated With Hypoglycemia in Adults With Type 1 and Type 2 Diabetes Mellitus That Participated in the Canadian Hypoglycemia Assessment Tool Program. Canadian Journal of Diabetes. 42:659-663. 2018
- Health Utilities Index Mark 3 scores for major chronic conditions: Population norms for Canada based on the 2013 and 2014 Canadian Community Health Survey.. Health Reports. 29:12-19. 2018
- Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older?. Canadian Journal of Cardiology. 34:1522-1525. 2018
- Regional variation in healthcare spending and mortality among senior high-cost healthcare users in Ontario, Canada: a retrospective matched cohort study. BMC Geriatrics. 18:262-262. 2018
- Effectiveness of a Type 2 Diabetes Screening Intervention in the Canadian Workplace. Canadian Journal of Diabetes. 42:493-499.e1. 2018
- Cognitive Impairment Mediates Workplace Impairment in Adults With Type 2 Diabetes Mellitus: Results From the Motivaction Study. Canadian Journal of Diabetes. 42:289-295. 2018
- Managing High‐Cost Healthcare Users: The International Search for Effective Evidence‐Supported Strategies. Journal of The American Geriatrics Society. 66:1002-1008. 2018
- Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada. PharmacoEconomics - Open. 2:19-29. 2018
- Age- and sex-specific Canadian utility norms, based on the 2013–2014 Canadian Community Health Survey. CANADIAN MEDICAL ASSOCIATION JOURNAL. 190:E155-E161. 2018
- A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. ClinicoEconomics and Outcomes Research. Volume 10:821-854. 2018
- Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. ClinicoEconomics and Outcomes Research. Volume 10:127-137. 2018
- Just how much does it cost? A cost study of chronic pain following cardiac surgery. Journal of Pain Research. Volume 11:2741-2759. 2018
- PP51 Updating Canadian Pharmaceutical Budget Impact Analysis Guidelines. International Journal of Technology Assessment in Health Care. 34:86-86. 2018
- Senior high-cost healthcare users’ resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada. BMJ Open. 7:e018488-e018488. 2017
- Low-intensity pulsed ultrasound for treatment of tibial fractures. The Bone & Joint Journal. 99-B:1526-1532. 2017
- Low-intensity pulsed ultrasound for treatment of tibial fractures AN ECONOMIC EVALUATION OF THE TRUST STUDY. The Bone & Joint Journal. 99B:1526-1532. 2017
- Effectiveness of a Diabetes Screening Intervention in the Canadian Workplace. Canadian Journal of Diabetes. 41:S28-S28. 2017
- CGS 37th Annual Scientific Meeting: Integrating Care, Making an Impact. Canadian Journal of Geriatrics. 20:198-239. 2017
- Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ open. 5:E653-E661. 2017
- Increase in Psychoactive Drug Prescriptions in the Years Following Autism Spectrum Diagnosis: A Population-Based Cohort Study. Journal of Population Therapeutics and Clinical Pharmacology. 24:e19-e32. 2017
- SENIOR HIGH COST HEALTHCARE USERS: HOW DO THEY DIFFER?. Innovation in Aging. 1:55-55. 2017
- What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review. Journal of Population Therapeutics and Clinical Pharmacology. 24:e1-e20. 2017
- Erratum to: The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. Obesity Surgery. 27:1128-1128. 2017
- The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. Obesity Surgery. 27:349-356. 2017
- Correction: Summary of Glaucoma Diagnostic Testing Accuracy: An Evidence-Based Meta-Analysis. Journal of Clinical Medicine Research. 9:231-231. 2017
- Illustration of the Impact of Unmeasured Confounding Within an Economic Evaluation Based on Nonrandomized Data. MDM Policy and Practice. 2:238146831769771-238146831769771. 2017
- Preliminary Results of the Adoption and Application of the Integrated Comprehensive Care Bundle Care Program When Treating Patients with Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal. 2017:1-10. 2017
- A comparison of health utility scores calculated using United Kingdom and Canadian preference weights in persons with alzheimer’s disease and their caregivers. Health and Quality of Life Outcomes. 14:105. 2016
- Loss of health related quality of life following low-trauma fractures in the elderly. BMC Geriatrics. 16:84. 2016
- Steps toward improving ethical evaluation in health technology assessment: a proposed framework. BMC Medical Ethics. 17:34. 2016
- The current economic burden of illness of osteoporosis in Canada. Osteoporosis International. 27:3023-3032. 2016
- A population-based analysis of the drivers of short-term costs after bariatric surgery within a publicly funded regionalized center of excellence system. Surgery for Obesity and Related Diseases. 12:1023-1031. 2016
- CYCLE pilot: a protocol for a pilot randomised study of early cycle ergometry versus routine physiotherapy in mechanically ventilated patients. BMJ Open. 6:e011659-e011659. 2016
- Summary of Glaucoma Diagnostic Testing Accuracy: An Evidence-Based Meta-Analysis. Journal of Clinical Medicine Research. 8:641-649. 2016
- Bridging the Gap between Evidence and Practice for Adults with Medically Refractory Temporal Lobe Epilepsy: Is a Change in Funding Policy Needed to Stimulate a Shift in Practice?. Epilepsy Research and Treatment. 2015:1-10. 2015
- Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations. BMC Research Notes. 8:244. 2015
- Psychiatric Healthcare Utilization and Related Costs In Newly Diagnosed Individuals With Autism Spectrum Disorder (Asd) In Quebec (Canada). Value in Health. 18:A746-A747. 2015
- Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies. Expert Review of Pharmacoeconomics and Outcomes Research. 15:451-463. 2015
- BARRIERS AND FACILITATORS INFLUENCING ETHICAL EVALUATION IN HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care. 31:113-123. 2015
- Caregivers’ willingness-to-pay for Alzheimer’s disease medications in Canada. Dementia. 14:63-79. 2015
- Impact on Health‐Related Quality of Life and Costs of Managing Chronic Neuropathic Pain in Academic Pain Centres: Results from a One‐Year Prospective Observational Canadian Study. Pain Research and Management. 20:327-333. 2015
- A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial. Trials. 15:268. 2014
- P2‐325: A COMPARISON OF HEALTH UTILITY SCORES CALCULATED USING UNITED KINGDOM AND CANADIAN PREFERENCE WEIGHTS IN AN ALZHEIMER'S DISEASE SAMPLE. Alzheimer's and Dementia. 10:p598-p598. 2014
- Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research. 14:203-220. 2014
- Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights. Value in Health. 17:77-83. 2014
- Access to surgery for paediatric patients with medically refractory epilepsy: A systems analysis. Journal of Epilepsy. 107:286-296. 2013
- Simulating an emergency department: the importance of modeling the interactions between physicians and delegates in a discrete event simulation. BMC Medical Informatics and Decision Making. 13:59. 2013
- Patients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada. Patient. 6:161-168. 2013
- HYPERBARIC OXYGEN THERAPY FOR DIABETIC ULCERS: SYSTEMATIC REVIEW AND META-ANALYSIS. International Journal of Technology Assessment in Health Care. 29:269-281. 2013
- Do Canadian Researchers and the Lay Public Prioritize Biomedical Research Outcomes Equally? A Choice Experiment. Academic Medicine. 88:519-526. 2013
- The Impact of Using Informative Priors in a Bayesian Cost-Effectiveness Analysis. Medical decision making. 33:437-450. 2013
- Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporosis International. 24:581-593. 2013
- The Burden of Atrial Fibrillation on the Hospital Sector in Canada. Canadian Journal of Cardiology. 29:229-235. 2013
- A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. Journal of the Canadian Urological Association. 7:335-335. 2013
- Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: adjusting for the burden of ensuing chronic kidney disease. Journal of the Canadian Urological Association. 7:108-13. 2013
- Photoselective vaporization for the treatment of benign prostatic hyperplasia.. Ontario Health Technology Assessment Series. 13:1-34. 2013
- The excess burden of rheumatoid arthritis in Ontario, Canada.. Clinical and Experimental Rheumatology. 31:18-24. 2013
- Economic Evaluations Conducted for Assessment of Genetic Testing Technologies: A Systematic Review. Genetic Testing and Molecular Biomarkers. 16:1322-1335. 2012
- PDB14 Characteristics of the Aboriginal People with Diabetes in the South-Western of Ontario, Canada. Value in Health. 15:A495-A496. 2012
- The General Publicʼs Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimerʼs Disease Medication. PharmacoEconomics (Auckland). 30:1085-1095. 2012
- The burden of illness of osteoporosis in Canada. Osteoporosis International. 23:2591-2600. 2012
- The burden of illness of osteoporosis in Canadian men. Journal of Bone and Mineral Research. 27:1830-1838. 2012
- P3‐312: The association between caregiver and patient health‐related quality‐of‐life in Alzheimer's disease. Alzheimer's and Dementia. 8:p568-p569. 2012
- Modeling cost–effectiveness of pharmaceuticals in Alzheimer's disease. Expert Review of Pharmacoeconomics and Outcomes Research. 12:275-277. 2012
- The economics of health information technology in medication management: a systematic review of economic evaluations. Journal of the American Medical Informatics Association : JAMIA. 19:423-438. 2012
- MATHEMATICAL MODELING: THE CASE OF EMERGENCY DEPARTMENT WAITING TIMES. International Journal of Technology Assessment in Health Care. 28:93-109. 2012
- Patient Management, and Time and Health Care Resource Utilization Associated with the Use of Intravenous Bisphosphonates For Patients with Metastatic Bone Disease: A Delphi Study. Hospital Practice. 40:131-137. 2012
- The excess burden of osteoarthritis in the province of Ontario, Canada. Arthritis and Rheumatism. 64:1153-1161. 2012
- Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporosis International. 23:921-927. 2012
- Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. Journal of Crohn's and Colitis. 6:77-85. 2012
- Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.. Journal of Population Therapeutics and Clinical Pharmacology. 19:e166-e178. 2012
- Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. ClinicoEconomics and Outcomes Research. 4:287-287. 2012
- Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada. ClinicoEconomics and Outcomes Research. 4:21-21. 2012
- A prospective, double-blind, randomized, controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy (HBOT) to standard wound care only for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus: a study protocol. Trials. 12:69. 2011
- Calculating Utility Decrements Associated With an Adverse Event. Medical decision making. 31:790-799. 2011
- Calculating Utility Decrements Associated With an Adverse Event: Marginal Tobit and CLAD Coefficients Should Be Used With Caution. Medical decision making. 31:790-799. 2011
- Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis. Seminars in Arthritis and Rheumatism. 41:178-186. 2011
- Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. Expert Review of Pharmacoeconomics and Outcomes Research. 11:513-521. 2011
- Health economic evaluations help inform payers of the best use of scarce health care resources.. International Journal of Circumpolar Health. 70:417-427. 2011
- Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Quality of Life Research. 20:939-943. 2011
- P3‐407: Patients’ and caregivers’ willingness to pay for a new Alzheimer's disease medication. Alzheimer's and Dementia. 7:s645-s646. 2011
- Ontario Multidetector Computed Tomographic Coronary Angiography Study. JAMA Internal Medicine. 171:1021-1029. 2011
- Health economic evaluations help inform payers of the best use of scarce health care resources. International Journal of Circumpolar Health. 70:419-427. 2011
- New glaucoma diagnostic technologies: a systematic review of economic studies. Canadian Journal of Ophthalmology. 46:89-91. 2011
- Bayesian Hierarchical Models Combining Different Study Types and Adjusting for Covariate Imbalances: A Simulation Study to Assess Model Performance. PLoS ONE. 6:e25635-e25635. 2011
- How Does the Canadian General Public Rate Moderate Alzheimer's Disease?. Journal of Aging Research. 2011:1-8. 2011
- Partnership in employee health. A workplace health program for British Columbia Public Service Agency (Canada). Work. 40:459-471. 2011
- Should Endovascular Repair Be Reimbursed for Low Risk Abdominal Aortic Aneurysm Patients? Evidence from Ontario, Canada. International Journal of Vascular Medicine. 2011:1-10. 2011
- Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. ClinicoEconomics and Outcomes Research. 3:89-89. 2011
- The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms. BMC Medical Research Methodology. 10:64. 2010
- Canadian Surgery Forum.. Canadian Journal of Surgery. 53:S51-S104. 2010
- General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. Expert Review of Pharmacoeconomics and Outcomes Research. 10:379-384. 2010
- Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. Value in Health. 13:487-494. 2010
- Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario. Value in Health. 13:S8-S11. 2010
- PMS58 HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO. Value in Health. 13:A133-A133. 2010
- PMS60 UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO. Value in Health. 13:A133-A134. 2010
- Reply by the Authors. Urology. 75:1236-1237. 2010
- Systematic Review and Meta-analysis of Transurethral Resection of the Prostate Versus Minimally Invasive Procedures for the Treatment of Benign Prostatic Obstruction. Urology. 75:1015-1022. 2010
- A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment. PharmacoEconomics (Auckland). 28:255-277. 2010
- An economic evaluation of surgery versus collagen injection for the treatment of female stress urinary incontinence.. Canadian Journal of Urology. 17:5087-5093. 2010
- Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature. Value in Health. 13:328-334. 2010
- Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study. European Journal of Health Economics. 11:27-34. 2010
- A review of health utilities across conditions common in paediatric and adult populations. Health and Quality of Life Outcomes. 8:12-12. 2010
- Capacity Constraints and Cost-Effectiveness: A Discrete Event Simulation for Drug-Eluting Stents. Medical decision making. 30:16-28. 2010
- Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Effectiveness and Resource Allocation. 8:14-14. 2010
- Evaluation of health outcomes in osteoarthritis patients after total knee replacement: a two-year follow-up. Health and Quality of Life Outcomes. 8:87-87. 2010
- Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada. BMC Health Services Research. 9:246. 2009
- The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. Journal of Medical Economics. 12:361-370. 2009
- Handling uncertainty in economic evaluations of patient level data: A review of the use of Bayesian methods to inform health technology assessments. International Journal of Technology Assessment in Health Care. 25:546-554. 2009
- Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Current Medical Research and Opinion. 25:1631-1633. 2009
- Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Reply. Current Medical Research and Opinion. 25:1632-1633. 2009
- P1‐208: How does the Canadian general public view moderate Alzheimer's disease? determination of health utility scores. Alzheimer's and Dementia. 5:p238-p238. 2009
- P1‐222: Canadians’ willingness to pay for Alzheimer's disease medications: Preliminary results of a study of the general public. Alzheimer's and Dementia. 5:p241-p241. 2009
- P2‐226: Public support for an annual tax increase to provide access to an Alzheimer's disease medication in Canada. Alzheimer's and Dementia. 5:p326-p327. 2009
- A review of the cost of cardiovascular disease. Canadian Journal of Cardiology. 25:e195-e202. 2009
- Approaches for Economic Evaluations of Health Care Technologies. Journal of the American College of Radiology. 6:307-316. 2009
- Conditionally Funded Field Evaluations and Practical Trial Design Within a Health Technology Assessment Framework. Journal of the American College of Radiology. 6:324-331. 2009
- Health Technology Assessment and Primary Data Collection for Reducing Uncertainty in Decision Making. Journal of the American College of Radiology. 6:332-342. 2009
- Health Technology Assessment for Radiologists: Basic Principles and Evaluation Framework. Journal of the American College of Radiology. 6:299-306. 2009
- Illustrating Economic Evaluation of Diagnostic Technologies: Comparing Helicobacter pylori Screening Strategies in Prevention of Gastric Cancer in Canada. Journal of the American College of Radiology. 6:317-323. 2009
- Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura. Clinical Therapeutics. 31:1082-1091. 2009
- Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. International Journal of Technology Assessment in Health Care. 25:196-207. 2009
- In search of the evidentiary foundation of published Canadian economic evaluations (2001–06). International Journal of Technology Assessment in Health Care. 25:214-221. 2009
- A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada. Value in Health. 12:245-252. 2009
- Excess Risk of Mortality and Complications Associated with Newly Diagnosed Cases of Diabetes in Ontario, Canada. Canadian Journal of Diabetes. 33:93-104. 2009
- Prevalence, Total and Excess Costs of Diabetes and Related Complications in Ontario, Canada. Canadian Journal of Diabetes. 33:35-45. 2009
- Reply. Journal of Vascular Surgery. 49:277-278. 2009
- The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.. Journal of Population Therapeutics and Clinical Pharmacology. 16:e346-e359. 2009
- A systematic review of the use of contingent valuation in Alzheimer's disease research. Dementia. 7:461-480. 2008
- The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Current Medical Research and Opinion. 24:3223-3237. 2008
- Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada. Journal of Vascular Surgery. 48:779-787. 2008
- Economic evaluations conducted by Canadian health technology assessment agencies: Where do we stand?. International Journal of Technology Assessment in Health Care. 24:437-444. 2008
- Universal or Targeted Screening for Fetal Alcohol Exposure: A Cost-Effectiveness Analysis. Journal of Studies on Alcohol and Drugs. 69:510-519. 2008
- Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients scheduled for total knee replacement. Quality of Life Research. 17:595-601. 2008
- Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Canadian Journal of Ophthalmology. 43:213-217. 2008
- Effects of study design and trends for EVAR versus OSR. Vascular Health and Risk Management. Volume 4:1011-1022. 2008
- Money matters: what to look for in an economic analysis. Acta Orthopaedica. 79:1-11. 2008
- Effectiveness and Safety of Drug-Eluting Stents in Ontario. New England Journal of Medicine. 357:1393-1402. 2007
- Can an Educational Program Optimize PDE5i Therapy? A Study of Canadian Primary Care Practices. Journal of Sexual Medicine. 4:1404-1413. 2007
- Treatment Satisfaction with Sildenafil in a Canadian Real-Life Setting. A 6-Month Prospective Observational Study of Primary Care Practices. Journal of Sexual Medicine. 4:1414-1421. 2007
- Costs of New Atypical Antipsychotic Agents for Schizophrenia: Does Unrestricted Access Reduce Hospital Utilization?. Healthcare Policy. 3:58-79. 2007
- Managing multiple projects: a literature review of setting priorities and a pilot survey of healthcare researchers in an academic setting.. Perspectives in health information management / AHIMA, American Health Information Management Association. 4:4. 2007
- Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Current Medical Research and Opinion. 23:671-682. 2007
- A Model for Assessing the Cost-Effectiveness of Atorvastatin and Simvastatin in Achieving Canadian Low-Density Lipoprotein Cholesterol Targets. Clinical Therapeutics. 29:519-528. 2007
- Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads. PharmacoEconomics (Auckland). 25:528-532. 2007
- Long-Term Cost-utility Analysis of a Multidisciplinary Primary Care Diabetes Management Program in Ontario. Canadian Journal of Diabetes. 31:205-214. 2007
- Painful Neuropathic Disorders: An Analysis of the RéGie De L’Assurance Maladie du QuéBec Database. Pain Research and Management. 12:31-37. 2007
- The humanistic burden of neuropathic pain in Canada. Journal of Medical Economics. 10:23-36. 2006
- Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clinical Therapeutics. 28:1922-1934. 2006
- Measuring quality of life: The development and initial validation of the Patient-Reported Erectile Function Assessment instrument. International Journal of Technology Assessment in Health Care. 22:372-378. 2006
- Persistence and adherence to cholesterol lowering agents: Evidence from Régie de l'Assurance Maladie du Québec data. American Heart Journal. 152:164-169. 2006
- The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function.. Canadian Journal of Urology. 13:3016-3025. 2006
- The economic burden of neuropathic pain in Canada. Journal of Medical Economics. 9:55-68. 2006
- The economic burden of schizophrenia in Canada in 2004. Current Medical Research and Opinion. 21:2017-2028. 2005
- Erectile dysfunction in spinal cord injury: a cost-utility analysis. Journal of Rehabilitation Medicine. 37:358-364. 2005
- A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada.. Journal of Population Therapeutics and Clinical Pharmacology. 11:e179-e190. 2004
- A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs. Value in Health. 4:16-31. 2001
- A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.. Managed Care Interface. 13:88-94. 2000
- Antidepressant selection for major depressive disorder: The budgetary impact on managed care. Drug Benefit Trends. 12. 2000
- A pharmacoeconomic evaluation of major depressive disorder (Italy). Epidemiology and Psychiatric Sciences. 8:220-231. 1999
- TPDM6: DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER. Value in Health. 2:152-152. 1999
- PCV10: A HEALTH ECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN BELGIUM. Value in Health. 2:27-27. 1999
- A health economic evaluation of hormone replacement therapy in belgium. International Journal of Fertility and Menopausal Studies. 43:224. 1998
- Evaluation of low acuity patients discharged from a virtual emergency department at a major urban academic health sciences centre in Toronto, Canada.. International Journal of Population Data Science. 7:1926.
- French Translation of the 2022 Version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Canadian Journal of Health Technologies. 3.
- Platform, Basket, and Umbrella Trial Designs: Issues Around Health Technology Assessment of Novel Therapeutics. Canadian Journal of Health Technologies. 2.
- Platform, Basket, and Umbrella Trial Designs: Stakeholder Perspectives of Novel Therapeutics. Canadian Journal of Health Technologies. 2.
- Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives. Canadian Journal of Health Technologies. 2.
-
preprints
- The iCARE feasibility non-experimental design study: An integrated collection of education modules for fall and fracture prevention for healthcare providers in long term care 2024
- Cost-utility analysis of low-dose pioglitazone in a population with prediabetes and a history of stroke and TIA 2023
- Robot-Assisted Partial Knee Replacement versus Standard Total Knee Replacement (RoboKnees): A Protocol for a Pilot Randomized Controlled Trial 2023
- Cost Evaluation of the Ontario Virtual Urgent Care Pilot Program: Population-Based, Matched Cohort Study (Preprint) 2023
- Improving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions on High Risk Medications (IMPROVE-IT HRM): A Pilot Randomized Trial Protocol 2023
- A multi-centre, randomized, 12-month, parallel-group, feasibility study to assess the acceptability and preliminary impact of family navigation plus usual care versus usual care on attrition in managing pediatric obesity: A study protocol 2022
- COORDINATION of ORAL ANTICOAGULANT CARE at HOSPITAL DISCHARGE (COACHeD): Protocol for a Pilot Randomised Controlled Trial 2022
- Molecular Test of Paget's Disease of Bone in Families Not Linked to SQSTM1 Gene Mutations 2022
- Examining Health Service Rates Among Residents of Retirement Homes and Other Older Adult Populations in Ontario, Canada: A Population-Based Cohort Study 2021
- Patient Characteristics and Determinants of CD4 at Diagnosis of HIV in Mexico from 2008 to 2017: A 10-Year Population-Based Study 2020
- Continuous Noninvasive Remote Automated Blood Pressure Monitoring With Novel Wearable Technology: A Preliminary Validation Study (Preprint) 2020
- A Multicenter Pilot Randomized Clinical Trial of Early In-Bed Cycle Ergometry with Ventilated Patients 2002